Nasdaq Extends Galmed's Deadline to Regain $1 Bid Compliance by 180 Days
GLMD sits 51% above its 52-week low of $0.411 on light trading volume (0.2× avg).
Summary
After failing to meet the $1 minimum bid price rule in the first 180-day period, Galmed has been given until January 25, 2027 by Nasdaq to regain compliance. The stock currently trades at $0.62.
Key Events · Legal and Risk Events · GLMD
-
Nasdaq Extension Granted
An additional 180-day compliance period has been granted by Nasdaq, giving Galmed until January 25, 2027 to meet the $1 minimum bid price rule.
-
Failed Initial Compliance Period
The company did not regain compliance during the first 180-day period that ended July 28, 2026, following the deficiency notice received on January 29, 2026.
-
Compliance Requirement
To satisfy the rule, the stock must close at or above $1 per share for at least 10 consecutive trading days before the deadline.
-
Current Price Gap
With the stock at $0.62, a roughly 60% increase is needed to reach $1, and the price must hold there for 10 consecutive days.
Analysis · GLMD · Life Sciences
A crucial lifeline has been extended to Galmed: Nasdaq has pushed the deadline to January 25, 2027 for the stock to climb back above $1. The company was unable to remedy the shortfall during the initial 180-day window that closed on July 28. Trading at $0.62, the shares need a 60% rally and must hold at or above $1 for 10 consecutive days to avert delisting. While the extension provides breathing room, the clock is running—and recent positive pipeline developments have yet to spark a sustained price recovery.
At the time of this filing, GLMD was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.41 to $1.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.